Direct comparison two fixed-ratio combination glucagon-like peptide receptor agonist and basal insulin on glycemic and non glycemic parameters in type 2 diabetes.

Risovic I, Dumanovic MS, Bojic M, Djekic D

BMC endocrine disorders1 Feb 2023Cited by 4 (Europe PMC)

PMID36726134PMCIDPMC9890870DOI10.1186/s12902-023-01282-wPepBankPUB-36726134

Summary

BackgroundTwo types of fixed-ratio combinations of basal insulin and a glucagon-like peptide-1 receptor agonist (GLP-1RA) have been approved for use in type 2 diabetes. One is insulin degludec/liraglutide (iDergLira), and the other is insulin glargine/lixisenatide (iGlarLixi). Direct comparisons between these two combination is not available.MethodsThe retrospective study included 186 patients with type 2 diabetes mellitus (DM) with inadequate glycemic control on metformin and basal insulin (degludec, glargine 100, glargine 300) who were switched to fixed-ratio combination GLP-1 RA and basal insulin. Patients were divided into two groups based on the basal insulin before study: group I (n = 86) treated with degludec were switched to iDegLira and patients group II (n = 99), treated with glargine were switched to iGlarLixi. The aim of this study was to directly compare the effects between two fixed - ratio combination on glycemic parameters and non glycemic parameters. Follow up was 6 months.ResultsMean HbA1c decreased similarly (- 1.2% vs.-1.1%). Higher percentage patients in iDegLira group had reached the HbA1c < 7% after 6 months (22% vs. 18.2%, p < 0.05). The mean change in fasting plasma glucose (FPG) was comparable for the two groups, while mean decrease postprandial plasma glucose (PPG) level were lower in iGlarLixi group (2 vs 1.8 mmol/l, p > 0.05). Change in body weight was significant in iDegLira group (1.8 kg vs. 0.7 kg, p < 0.001). At the end of the study patients showed decrease in total cholesterol (TC) and low-density lipoprotein (LDL) for 0.2 mmol/L in iDegLira, 0.1 mmol/l in iGlarLixi, triglycerides decreased 0.3 mmol/l in both groups, high-density lipoprotein(HDL) increased 0.1 mm/l in iGlarLixi.ConclusionOur results showed that more patients with iDegLira had HbA1c less than 7% and these combination had better effect on weight loss. There was no difference observed in FPG and PPG, lipid profile and rate of hypoglycemia.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study10

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone10

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In adults with type 2 diabetes, HbA1c fell similarly after switching to insulin degludec/liraglutide (1.2%) and insulin glargine/lixisenatide (1.1%).
In plain wordsIn adults with type 2 diabetes, a fixed insulin plus GLP-1 product containing liraglutide lowered HbA1c about as much as a similar product with lixisenatide.
Peptide
Liraglutide
Outcome
No significant changeHbA1c change at 6 months
Study
n = 186
Comparator
Insulin glargine/lixisenatide (iGlarLixi)
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c decrease
1.2%
iDegLira
HbA1c decrease
1.1%
iGlarLixi
Source sentences
Summary
Mean HbA1c decreased similarly (- 1.2% vs.-1.1%).
2 context sentences(design, population, supporting numbers)
Summary · context
The retrospective study included 186 patients with type 2 diabetes mellitus (DM) with inadequate glycemic control on metformin and basal insulin (degludec, glargine 100, glargine 300) who were switched to fixed-ratio combination GLP-1 RA and basal insulin.
Summary · context
Patients were divided into two groups based on the basal insulin before study: group I (n = 86) treated with degludec were switched to iDegLira and patients group II (n = 99), treated with glargine were switched to iGlarLixi.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3672613401
02HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In adults with type 2 diabetes, more patients reached HbA1c below 7% with insulin degludec/liraglutide than with insulin glargine/lixisenatide (22% vs 18.2%, p < 0.05).
In plain wordsIn adults with type 2 diabetes, slightly more patients reached HbA1c below 7% with the liraglutide-containing combination than with the lixisenatide combination.
Peptide
Liraglutide
Outcome
IncreaseHbA1c below 7% at 6 months
Study
n = 186
Comparator
Insulin glargine/lixisenatide (iGlarLixi)
Outcome group
Glycemic control · Metabolic and weight
Measurements
Proportion with HbA1c <7%
22%
iDegLira
Proportion with HbA1c <7%
18.2%
iGlarLixi
Source sentences
Summary
Higher percentage patients in iDegLira group had reached the HbA1c < 7% after 6 months (22% vs. 18.2%, p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
The retrospective study included 186 patients with type 2 diabetes mellitus (DM) with inadequate glycemic control on metformin and basal insulin (degludec, glargine 100, glargine 300) who were switched to fixed-ratio combination GLP-1 RA and basal insulin.
Summary · context
Patients were divided into two groups based on the basal insulin before study: group I (n = 86) treated with degludec were switched to iDegLira and patients group II (n = 99), treated with glargine were switched to iGlarLixi.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3672613402
03HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In adults with type 2 diabetes, the mean change in fasting plasma glucose was comparable between insulin degludec/liraglutide and insulin glargine/lixisenatide.
In plain wordsIn adults with type 2 diabetes, fasting blood sugar changed by a similar amount with the liraglutide combination and the lixisenatide combination.
Peptide
Liraglutide
Outcome
No significant changeFasting plasma glucose change
Study
n = 186
Comparator
Insulin glargine/lixisenatide (iGlarLixi)
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
The mean change in fasting plasma glucose (FPG) was comparable for the two groups
2 context sentences(design, population, supporting numbers)
Summary · context
The retrospective study included 186 patients with type 2 diabetes mellitus (DM) with inadequate glycemic control on metformin and basal insulin (degludec, glargine 100, glargine 300) who were switched to fixed-ratio combination GLP-1 RA and basal insulin.
Summary · context
Patients were divided into two groups based on the basal insulin before study: group I (n = 86) treated with degludec were switched to iDegLira and patients group II (n = 99), treated with glargine were switched to iGlarLixi.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3672613403
04HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In adults with type 2 diabetes, the postprandial glucose decrease was 2 mmol/l with insulin degludec/liraglutide and 1.8 mmol/l with insulin glargine/lixisenatide, without a significant difference (p > 0.05).
In plain wordsIn adults with type 2 diabetes, after-meal blood sugar fell by a similar amount with the liraglutide combination and the lixisenatide combination.
Peptide
Liraglutide
Outcome
No significant changePostprandial plasma glucose decrease
Study
n = 186
Comparator
Insulin glargine/lixisenatide (iGlarLixi)
Outcome group
Glycemic control · Metabolic and weight
Measurements
PPG decrease
2 mmol/l
iDegLira
PPG decrease
1.8 mmol/l
iGlarLixi
Source sentences
Summary
while mean decrease postprandial plasma glucose (PPG) level were lower in iGlarLixi group (2 vs 1.8 mmol/l, p > 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
The retrospective study included 186 patients with type 2 diabetes mellitus (DM) with inadequate glycemic control on metformin and basal insulin (degludec, glargine 100, glargine 300) who were switched to fixed-ratio combination GLP-1 RA and basal insulin.
Summary · context
Patients were divided into two groups based on the basal insulin before study: group I (n = 86) treated with degludec were switched to iDegLira and patients group II (n = 99), treated with glargine were switched to iGlarLixi.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3672613404
05HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In adults with type 2 diabetes, body weight change was greater with insulin degludec/liraglutide than with insulin glargine/lixisenatide (1.8 kg vs 0.7 kg, p < 0.001).
In plain wordsIn adults with type 2 diabetes, weight loss was greater with the liraglutide-containing combination than with the lixisenatide combination.
Peptide
Liraglutide
Outcome
DecreaseBody weight change
Study
n = 186
Comparator
Insulin glargine/lixisenatide (iGlarLixi)
Outcome group
Body weight · Metabolic and weight
Measurements
Weight change
1.8 kg
iDegLira
Weight change
0.7 kg
iGlarLixi
Source sentences
Summary
Change in body weight was significant in iDegLira group (1.8 kg vs. 0.7 kg, p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
The retrospective study included 186 patients with type 2 diabetes mellitus (DM) with inadequate glycemic control on metformin and basal insulin (degludec, glargine 100, glargine 300) who were switched to fixed-ratio combination GLP-1 RA and basal insulin.
Summary · context
Patients were divided into two groups based on the basal insulin before study: group I (n = 86) treated with degludec were switched to iDegLira and patients group II (n = 99), treated with glargine were switched to iGlarLixi.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3672613405
06HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In adults with type 2 diabetes, total cholesterol fell by 0.2 mmol/L with insulin degludec/liraglutide and by 0.1 mmol/L with insulin glargine/lixisenatide.
In plain wordsIn adults with type 2 diabetes, total cholesterol fell by a small amount with both insulin combinations.
Peptide
Liraglutide
Outcome
DecreaseTotal cholesterol change
Study
n = 186
Comparator
Insulin glargine/lixisenatide (iGlarLixi)
Outcome group
Lipids · Cardiovascular
Measurements
Total cholesterol decrease
0.2 mmol/L
iDegLira
Total cholesterol decrease
0.1 mmol/l
iGlarLixi
Source sentences
Summary
At the end of the study patients showed decrease in total cholesterol (TC) and low-density lipoprotein (LDL) for 0.2 mmol/L in iDegLira, 0.1 mmol/l in iGlarLixi, triglycerides decreased 0.3 mmol/l in both groups, high-density lipoprotein(HDL) increased 0.1 mm/l in iGlarLixi.
2 context sentences(design, population, supporting numbers)
Summary · context
The retrospective study included 186 patients with type 2 diabetes mellitus (DM) with inadequate glycemic control on metformin and basal insulin (degludec, glargine 100, glargine 300) who were switched to fixed-ratio combination GLP-1 RA and basal insulin.
Summary · context
Patients were divided into two groups based on the basal insulin before study: group I (n = 86) treated with degludec were switched to iDegLira and patients group II (n = 99), treated with glargine were switched to iGlarLixi.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3672613406
07HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In adults with type 2 diabetes, LDL cholesterol fell by 0.2 mmol/L with insulin degludec/liraglutide and by 0.1 mmol/L with insulin glargine/lixisenatide.
In plain wordsIn adults with type 2 diabetes, LDL cholesterol fell by a small amount with both insulin combinations.
Peptide
Liraglutide
Outcome
DecreaseLDL cholesterol change
Study
n = 186
Comparator
Insulin glargine/lixisenatide (iGlarLixi)
Outcome group
Lipids · Cardiovascular
Measurements
LDL decrease
0.2 mmol/L
iDegLira
LDL decrease
0.1 mmol/l
iGlarLixi
Source sentences
Summary
At the end of the study patients showed decrease in total cholesterol (TC) and low-density lipoprotein (LDL) for 0.2 mmol/L in iDegLira, 0.1 mmol/l in iGlarLixi, triglycerides decreased 0.3 mmol/l in both groups, high-density lipoprotein(HDL) increased 0.1 mm/l in iGlarLixi.
2 context sentences(design, population, supporting numbers)
Summary · context
The retrospective study included 186 patients with type 2 diabetes mellitus (DM) with inadequate glycemic control on metformin and basal insulin (degludec, glargine 100, glargine 300) who were switched to fixed-ratio combination GLP-1 RA and basal insulin.
Summary · context
Patients were divided into two groups based on the basal insulin before study: group I (n = 86) treated with degludec were switched to iDegLira and patients group II (n = 99), treated with glargine were switched to iGlarLixi.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3672613407
08HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In adults with type 2 diabetes, triglycerides fell by 0.3 mmol/l in both the insulin degludec/liraglutide and insulin glargine/lixisenatide groups.
In plain wordsIn adults with type 2 diabetes, triglycerides fell by the same small amount with both insulin combinations.
Peptide
Liraglutide
Outcome
DecreaseTriglyceride change
Study
n = 186
Comparator
Insulin glargine/lixisenatide (iGlarLixi)
Outcome group
Lipids · Cardiovascular
Measurements
Triglyceride decrease
0.3 mmol/l
both groups
Source sentences
Summary
At the end of the study patients showed decrease in total cholesterol (TC) and low-density lipoprotein (LDL) for 0.2 mmol/L in iDegLira, 0.1 mmol/l in iGlarLixi, triglycerides decreased 0.3 mmol/l in both groups, high-density lipoprotein(HDL) increased 0.1 mm/l in iGlarLixi.
2 context sentences(design, population, supporting numbers)
Summary · context
The retrospective study included 186 patients with type 2 diabetes mellitus (DM) with inadequate glycemic control on metformin and basal insulin (degludec, glargine 100, glargine 300) who were switched to fixed-ratio combination GLP-1 RA and basal insulin.
Summary · context
Patients were divided into two groups based on the basal insulin before study: group I (n = 86) treated with degludec were switched to iDegLira and patients group II (n = 99), treated with glargine were switched to iGlarLixi.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3672613408
09HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In adults with type 2 diabetes, no difference in lipid profile was seen between insulin degludec/liraglutide and insulin glargine/lixisenatide.
In plain wordsIn adults with type 2 diabetes, cholesterol and fat levels did not differ between the two insulin combinations.
Peptide
Liraglutide
Outcome
No significant changeLipid profile difference between groups
Study
n = 186
Comparator
Insulin glargine/lixisenatide (iGlarLixi)
Outcome group
Lipids · Cardiovascular
Source sentences
Summary
There was no difference observed in FPG and PPG, lipid profile and rate of hypoglycemia.
2 context sentences(design, population, supporting numbers)
Summary · context
The retrospective study included 186 patients with type 2 diabetes mellitus (DM) with inadequate glycemic control on metformin and basal insulin (degludec, glargine 100, glargine 300) who were switched to fixed-ratio combination GLP-1 RA and basal insulin.
Summary · context
Patients were divided into two groups based on the basal insulin before study: group I (n = 86) treated with degludec were switched to iDegLira and patients group II (n = 99), treated with glargine were switched to iGlarLixi.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3672613409
10HumanNot a test of Liraglutide aloneObservational studySafety outcome
In adults with type 2 diabetes, the rate of hypoglycemia did not differ between insulin degludec/liraglutide and insulin glargine/lixisenatide.
In plain wordsIn adults with type 2 diabetes, low blood sugar events were not more common with the liraglutide combination than the lixisenatide combination.
Peptide
Liraglutide
Outcome
No significant changeRate of hypoglycemia
Study
n = 186
Comparator
Insulin glargine/lixisenatide (iGlarLixi)
Outcome group
Adverse events · Metabolic and weight
Source sentences
Summary
There was no difference observed in FPG and PPG, lipid profile and rate of hypoglycemia.
2 context sentences(design, population, supporting numbers)
Summary · context
The retrospective study included 186 patients with type 2 diabetes mellitus (DM) with inadequate glycemic control on metformin and basal insulin (degludec, glargine 100, glargine 300) who were switched to fixed-ratio combination GLP-1 RA and basal insulin.
Summary · context
Patients were divided into two groups based on the basal insulin before study: group I (n = 86) treated with degludec were switched to iDegLira and patients group II (n = 99), treated with glargine were switched to iGlarLixi.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3672613410

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
27 Oct 2026, 16:36 UTC
Study data updated · source update from Europe PMC
Version 2
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Direct comparison two fixed-ratio combination glucagon-like peptide receptor agonist and basal insulin on glycemic and non glycemic parameters in type 2 diabetes.

Summary

Results from this study10

Studies that did not test the peptide alone10

Version history

Subjects

Publication types

MeSH terms

Keywords